A
Alcista
Alcista · 25%QNRX
$8.61
Precio del escenario
$3.650
-0.189 (-5.19%)Al cierre
Loading chart…
- Máximo
- 4.020
- Apertura
- 3.790
- Precio medio ponderado por volumen
- 3.71
- Volumen
- 25.48K
- Capitalización
- 2.35M
- Mínimo
- 3.450
- Importe
- 94.44K
- EV/EBITDA, TTM
- 0.00
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Análisis de IA of Quoin Pharmaceuticals Ltd (QNRX)
VenderQuoin Pharmaceuticals Ltd is not a good buy right now due to its current price of $3.65, which is significantly below analyst targets of $12 and $20. The stock has a very low RSI of 28.67, indicating it is oversold, but the company has reported consistent net losses, with a net income of -5,371,042 USD in Q2 2026. The main risk is the company's ongoing financial struggles, as indicated by a 74.08% year-to-date decline in stock price.
Métricas de valoración
El PER previsto actual de Quoin Pharmaceuticals Ltd (QNRX) es 0.00, frente a su media de 5 años de -1.08.
Escenarios de precio de Alphio AI para QNRX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.511-06NewsfilterQuoin Pharmaceuticals Releases New Netherton NOW Episode Featuring Patient Insights
- 9.010-20Newsfilter
QRX003 Shows Promising Results in Netherton Syndrome Treatment
- 9.010-14Newsfilter
Quoin Pharmaceuticals Secures Orphan Drug Designation for Peeling Skin Syndrome
9.009-23NASDAQ.COMQuoin Pharmaceuticals Receives FDA Fast Track Designation for QRX003
- 8.509-10Newsfilter
Quoin Pharmaceuticals Releases New Episode of NETHERTON NOW Video Series
Preguntas frecuentes sobre QNRX, respondidas por Alphio AI
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Quoin Pharmaceuticals Ltd is not a good buy right now due to its current price of $3.65, which is significantly below analyst targets of $12 and $20. The stock has a very low RSI of 28.67, indicating it is oversold, but the company has reported consistent net losses, with a net income of -5,371,042 USD in Q2 2026. The main risk is the company's ongoing financial struggles, as indicated by a 74.08% year-to-date decline in stock price.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.